URL has been copied successfully!
On Wednesday, the Food and Drug Administration’s approved mFlusiva, the first mRNA seasonal influenza vaccine ever licensed in this country. In June the agency’s own advisory committee voted unanimously that its benefits outweigh its risks in adults 50 to 64, then unanimously again for adults 65 and older. Nine independent experts, appointed by this government, could not produce a single vote against it.
Wednesday was also an anniversary. On Aug. 5, 2025, the Department of Health and Human Services killed 22 mRNA vaccine development projects worth roughly $500 million and ordered a halt to federal investment in the platform.
Please follow us:
